05 October 2016

Prospero House, 241 Borough High Street, London

Draft Agenda

The meeting will start promptly at 10am and is expected to finish at approximately 6pm.

Please note that this agenda is subject to change prior to the meeting.

  1. Welcome and introduction to format of meeting – Part 1 only (open session)
  2. Code of conduct for members of the public attending the meeting – Part 1 only (open session)
  3. Apologies – Part 1 only (open session)
  4. Any other business – Part 1 only (open session)
  5. Minutes from the last Committee meeting held on 7 September 2016 – Part 1 only (open session)
  6. Appraisal of ixekizumab for treating moderate to severe plaque psoriasis [ID904]
    • 6.1. Declarations of interest – Part 1 only (open session)
    • 6.2. Introduction by the Chair, Dr Amanda Adler – Part 1 only (open session)
    • 6.3. Presentation by the Lead team – Part 1 AND part 2 (open and closed session)
    • 6.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  7. Appraisal of lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib (partial review of TA171) [ID667]
    • 7.1. Declarations of interest – Part 1 only (open session)
    • 7.2. Introduction by the Chair, Dr Amanda Adler – Part 1 only (open session)
    • 7.3. Presentation by the Chair, Dr Amanda Adler – Part 1 AND part 2 (open and closed session)
    • 7.4. Agreement on the content of the Final Appraisal Determination (FAD) – Part 2 only (closed session)
  8. Appraisal of mepolizumab for treating severe eosinophilic asthma [ID798]
    • 8.1. Declarations of interest – Part 1 only (open session)
    • 8.2. Introduction by the Chair, Dr Amanda Adler – Part 1 only (open session)
    • 8.3. Presentation by the Chair, Dr Amanda Adler – Part 1 AND part 2 (open and closed session)
    • 8.4. Agreement on the content of the Final Appraisal Determination (FAD) – Part 2 only (closed session)
  9. Appraisal of ibrutinib for treating chronic lymphocytic leukaemia [ID749]
    1. 9.1.  Declarations of interest - Part 1 only (open session)
    2. 9.2. Introduction by Chair, Dr Amanda Adler - Part 2 only (closed session)
    3. 9.3. Presentation by the Chair, Dr Amanda Adler - Part 2 only (closed session)
    4. 9.4. Agreement on the content of the Final Appraisal Determination (FAD) - Part 2 only (closed session)

To print an agenda, please right click and select 'Print' from the menu.

Date, time and venue of next meeting

The next meeting will take place on 2 November 2016, at Prospero House, 241 Borough High Street, London, SE1 1GA.

Please note all timings are approximate.

How to register

  • Click on the register link below and complete the registration form, selecting the topics you would like to attend.
  • You will receive an automated email response when you submit the registration form. If you do not receive this automated response your registration request has not been received, and you will need to complete and submit the registration form again.
  • Registration will close on 23 September 2016Please note that it may not be possible to accept late requests. 
  • Should you have queries regarding attending this meeting, please contact the Meetings in Public Coordinator Josh South.
  • Registrants wishing to conduct a research study on committee meetings and/or NICE processes will require prior permission. Contact the NICE Enquiry Handling team at nice@nice.org.uk.
  • Further information about conducting research is also available in our common questions and answers about meetings in public document.

 

Registration period: 09 to 23 September 2016
Registration is closed.